Compare · IBM vs OMCL
IBM vs OMCL
Side-by-side comparison of International Business Machines Corporation (IBM) and Omnicell Inc. (OMCL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBM and OMCL operate in Computer Manufacturing (Technology), so they compete in similar markets.
- IBM is the larger of the two at $283.63B, about 143.0x OMCL ($1.98B).
- Over the past year, IBM is up 13.0% and OMCL is up 41.3% - OMCL leads by 28.2 points.
- OMCL has been more active in the news (16 items in the past 4 weeks vs 13 for IBM).
- IBM has more recent analyst coverage (25 ratings vs 24 for OMCL).
- Company
- International Business Machines Corporation
- Omnicell Inc.
- Price
- $301.79-1.35%
- $43.60+4.13%
- Market cap
- $283.63B
- $1.98B
- 1M return
- +31.78%
- +0.14%
- 1Y return
- +13.04%
- +41.28%
- Industry
- Computer Manufacturing
- Computer Manufacturing
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- News (4w)
- 13
- 16
- Recent ratings
- 25
- 24
International Business Machines Corporation
International Business Machines Corporation provides integrated solutions and services worldwide. Its Cloud & Cognitive Software segment offers software for vertical and domain-specific solutions in various application areas; and customer information control system and storage, and analytics and integration software solutions to support client mission on-premise workloads in banking, airline, and retail industries. It also offers middleware and data platform software, including Red Hat that enables the operation of clients' hybrid multi-cloud environments; and Cloud Paks, WebSphere distributed, and analytics platform software, such as DB2 distributed, information integration, and enterprise content management, as well as IoT, Blockchain and AI/Watson platforms. The company's Global Business Services segment offers business consulting services; system integration, application management, maintenance, and support services for packaged software; and finance, procurement, talent and engagement, and industry-specific business process outsourcing services. Its Global Technology Services segment provides IT infrastructure and platform services; and project, managed, outsourcing, and cloud-delivered services for enterprise IT infrastructure environments; and IT infrastructure support services. The company's Systems segment offers servers for businesses, cloud service providers, and scientific computing organizations; data storage products and solutions; and z/OS, an enterprise operating system, as well as Linux. Its Global Financing segment provides lease, installment payment, loan financing, short-term working capital financing, and remanufacturing and remarketing services. The company has a collaboration alliance with GK Software SE to enhance retail innovation and customer omnichannel experience with hybrid cloud technology. The company was formerly known as Computing-Tabulating-Recording Co. The company was incorporated in 1911 and is headquartered in Armonk, New York.
Omnicell Inc.
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Latest IBM
- VP, Controller Fehring Nicolas A. gifted 400 shares, decreasing direct ownership by 2% to 16,578 units (SEC Form 4)
- IBM and Google Cloud Announce Strategic Partnership to Scale AI with Human Expertise and AI‑Powered Delivery
- IBM Launches Global AI Builders Challenge With IBM Bob for University Students, Expanding Availability of IBM Bob to 20,000 Post-Secondary Institutions Worldwide
- IBM Commits More Than $10 Billion to Quantum Computing, Funding Its Roadmap from Today's Leading Systems to the World's First Fault-Tolerant Quantum Computers
- SEC Form SD filed by International Business Machines Corporation
- Barclays initiated coverage on IBM with a new price target
- International Business Machines Corporation filed SEC Form 8-K: Regulation FD Disclosure
- IBM and Red Hat Commit $5 Billion to Redefine the Future of Open Source in the AI Era
- IBM and Abertis are Driving the Future of Mobility with a Global Technology Modernization Agreement
- IBM and U.S. Department of Commerce Announce America's First Purpose-Built Quantum Foundry, Supported by Proposed $1 Billion CHIPS Award
Latest OMCL
- Director Bousa Edward Peter was granted 4,603 shares, increasing direct ownership by 26% to 22,589 units (SEC Form 4)
- Director Scott Bruce E was granted 4,627 shares, increasing direct ownership by 20% to 27,600 units (SEC Form 4)
- Director Seim Robin Gene was granted 4,845 shares, increasing direct ownership by 10% to 52,198 units (SEC Form 4)
- Director Voynick Eileen J. was granted 4,785 shares, increasing direct ownership by 31% to 20,011 units (SEC Form 4)
- Director Parrish Mark W was granted 4,845 shares, increasing direct ownership by 7% to 70,100 units (SEC Form 4)
- Director Bauer Joanne B was granted 5,027 shares, increasing direct ownership by 11% to 49,922 units (SEC Form 4)
- Director Garrett Mary was granted 5,027 shares, increasing direct ownership by 29% to 22,202 units (SEC Form 4)
- Director Ghoshal Kaushik was granted 4,603 shares, increasing direct ownership by 32% to 19,123 units (SEC Form 4)
- Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- SEC Form SD filed by Omnicell Inc.